All In Biotech

Drug Trial Radar · NCT05181618

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

A Multicenter, Open-Label Phase IV Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes, in Participants Aged ≥13 and <70 Years With Severe or Moderate Hemophilia A Without FVIII Inhibitors on Emicizumab Prophylaxis

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

136

Actual

Start

Jun 20, 2022

Primary completion

Nov 19, 2026

Study completion Dec 21, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 13 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study MO42623 is a Phase IV, multicenter, open-label, three cohort study designed to evaluate the impact of emicizumab prophylaxis on overall health, physical activity, and joint outcomes in participants aged ≥13 and \<70 years with severe hemophilia A without factor VIII (FVIII) inhibitors or moderate hemophilia A without FVIII inhibitors who are receiving FVIII prophylaxis and who will start emicizumab treatment as part of this study.

Conditions

  • Severe Hemophilia A
  • Moderate Hemophilia A

Interventions

  • EmicizumabDrug

    The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Joint Status at 6 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with SynovitisTime frame: 6 Months
  2. Joint Status at 12 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with SynovitisTime frame: 12 Months
  3. Joint Status at 24 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with SynovitisTime frame: 24 Months
  4. Joint Status at 36 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with SynovitisTime frame: 36 Months
  5. Clinical Joint Status at 6 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait AssessmentTime frame: 6 Months
  6. Clinical Joint Status at 12 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait AssessmentTime frame: 12 Months
  7. Clinical Joint Status at 24 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait AssessmentTime frame: 24 Months
  8. Clinical Joint Status at 36 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait AssessmentTime frame: 36 Months
  9. Joint Status at 36 Months, Based on Centrally Reviewed International Prophylaxis Study Group (IPSG) Score (with MRI)Time frame: 36 Months
  10. Number of Problem Joints at 6 MonthsTime frame: 6 Months
  11. Number of Problem Joints at 12 MonthsTime frame: 12 Months
  12. Number of Problem Joints at 24 MonthsTime frame: 24 Months
  13. Number of Problem Joints at 36 MonthsTime frame: 36 Months
  14. Percentage of Joints That are Problem Joints at 6 MonthsTime frame: 6 Months
  15. Percentage of Joints That are Problem Joints at 12 MonthsTime frame: 12 Months
  16. Percentage of Joints That are Problem Joints at 24 MonthsTime frame: 24 Months
  17. Percentage of Joints That are Problem Joints at 36 MonthsTime frame: 36 Months
  18. Change from Baseline in the CATCH Domain Scores Over Time, as Assessed with the Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) Questionnaire for Adult ParticipantsTime frame: At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
  19. Change from Baseline in the CATCH Domain Scores Over Time, as Assessed with the CATCH Questionnaire for Pediatric ParticipantsTime frame: At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
  20. Change from Baseline in the Average Daily Time Spent Doing Physical Activities by Intensity Level Over Time, as Assessed by Participant Responses to the International Physical Activity Questionnaire Short Format (IPAQ-SF)Time frame: At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
  21. Daily Step Count Over Time, as Measured with a Wearable Activity TrackerTime frame: From Baseline until end of treatment period (up to 36 months)
  22. Daily Metabolic Equivalents of Tasks (METs) Over Time, as Measured with a Wearable Activity TrackerTime frame: From Baseline until end of treatment period (up to 36 months)
  23. Daily Time Spent in Moderate to Vigorous Physical Activity (MVPA) Over Time, as per the Activity Tracker Default CategorizationTime frame: From Baseline until end of treatment period (up to 36 months)
  24. Daily Active Minutes of Physical Activity Over Time, as Measured with a Wearable Activity TrackerTime frame: From Baseline until end of treatment period (up to 36 months)
  25. Model-Based Annualized Bleed Rates for All Bleeds, Treated Bleeds, Spontaneous Bleeds, Joint Bleeds, Treated Joint Bleeds, and Target Joint BleedsTime frame: From Baseline until end of treatment period (up to 36 months)
  26. Mean Calculated Annualized Bleed Rates for All Bleeds, Treated Bleeds, Spontaneous Bleeds, Joint Bleeds, Treated Joint Bleeds, and Target Joint BleedsTime frame: From Baseline until end of treatment period (up to 36 months)
  27. Median Calculated Annualized Bleed Rates for All Bleeds, Treated Bleeds, Spontaneous Bleeds, Joint Bleeds, Treated Joint Bleeds, and Target Joint BleedsTime frame: From Baseline until end of treatment period (up to 36 months)
  28. Number of Participants who Prefer Emicizumab SC Treatment, Their Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Month 6Time frame: At Month 6

Locations

26 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Miami Medical Center

    Miami, Florida

  • Oklahoma Children's Hospital ? Jimmy Everest Center

    Oklahoma City, Oklahoma

  • Hospital das Clinicas - UNICAMP

    Campinas, São Paulo, Brazil

  • Hospital das Clínicas Faculdades Médicas de Ribeirão Preto

    Ribeirão Preto, São Paulo, Brazil

  • Hamilton Health Sciences Corporation

    Hamilton, Ontario, Canada

  • Charité Universitätsklinikum Berlin

    Berlin, Germany

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Észak-Pesti Centrumkórház - Honvédkórház

    Budapest, Hungary

  • Policlinico Univ. A. Gemelli

    Rome, Lazio, Italy

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy

  • AOU Careggi

    Florence, Tuscany, Italy

  • Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique

    Rabat, Morocco

  • University Clinical Centre of Serbia

    Belgrade, Serbia

  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario Vall de Hebron

    Barcelona, Spain

  • Hospital Universitario la Paz

    Madrid, Spain

  • Hospital Regional Universitario Carlos Haya

    Málaga, Spain

  • CHU Farhat Hached

    Sousse, Tunisia

  • Aziza Othmana Hospital

    Tunis, Tunisia

  • Gazi Universitesi Tip Fakultesi

    Ankara, Turkey (Türkiye)

  • Akdeniz Uni School of Medicine

    Antalya, Turkey (Türkiye)

  • Istanbul University Cerrahpasa Medical Faculty

    Istanbul, Turkey (Türkiye)

  • Ege Uni Medical School

    Izmir, Turkey (Türkiye)

  • St Thomas Westminster

    London, United Kingdom

  • Manchester University NHS Foundation Trust (MFT)

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.